Download Pulmonary Vein Isolation Using a Visually

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Remote ischemic conditioning wikipedia , lookup

Cardiac contractility modulation wikipedia , lookup

Management of acute coronary syndrome wikipedia , lookup

Lutembacher's syndrome wikipedia , lookup

Cardiac surgery wikipedia , lookup

History of invasive and interventional cardiology wikipedia , lookup

Dextro-Transposition of the great arteries wikipedia , lookup

Quantium Medical Cardiac Output wikipedia , lookup

Transcript
DOI: 10.1161/CIRCEP.113.000431
who underwent ablation near the end of the 200 patient series were excluded as baseline
demographics and procedural data were not available at the time of data analysis; however, none
of these excluded patients experienced any procedural complications. All of the studies were
approved by institutional review committees at the participating institutions, and all subjects
gave informed consent. The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree with the manuscript as written.
Patient Selection & Study Design: All 4 clinical studies were open label, non-randomized
Downloaded from http://circep.ahajournals.org/ by guest on November 1, 2016
studies of patients with symptomatic, recurrent, paroxysmal AF. There
minimal
re were only
y mini
ima
mal
differences in the inclusion criteria between the studies. Key inclusionn criteria
age
crite
t riia were:
te
were
we
re:: ag
ge 18
118-75
8
years, and recurrent
that
refractory
r cur
rec
urre
r ntt paroxysmal
re
parox
oxxysmal atrial fibrillation th
hat
at was refractor
o y to at least one antiarrhythmicc ddrug
IV).
All
patients
otherwise
ruug (Class I – IV
V). A
lll pati
tiientts were
weeree ot
the
herw
wis
isee deemed
deem
med ttoo bee candidates
candi
diidatess for
foor catheter
caa
ablation. Key
criteria
K exclusion
exc
xclu
lu
lusion
u
crit
iteriia included:
it
inclu
lu
uded:
de a left
de
left
ft ventricular
venttriicular
ullar ejection
eje
jectio
ionn fraction
io
f acti
fr
t onn <30%,
<30%,
% LA
LA diameter
dia
di
ia
>5 cm, PV diameters >32
PVs,
the
major
minor
322 mm (f
(for oval PV
P
s, th
he mean off tthe
he maj
ajoor and
aj
ndd mi
inor ddimensions
imen
ensi
en
s ons were
si
used), the presence off an intracardiac
thrombus,
ablation,
myocardial
intt cardi
dia th
thromb
mb
b s prior
io cardiac
rdi
dia abl
ablation
blati
ti
m ocardial
diall iinfarction
infarctio
nff cti
tio or
cardiac surgery within the prior 3 months, moderate or severe valvular heart disease, or a
stroke/transient ischemic attack within prior 6 months. Pre-procedural CT or MRI scans were
performed to assess LA and PV anatomy and size.
Following the procedure, patients were discharged on oral anticoagulation (warfarin), and
at times, low molecular weight heparin until the international normalized ratio was t2.0.
Following the procedure, anti-arrhythmic medications were typically continued for 1 to 3 months
after which they were completely discontinued. There was a 3 month blanking period following
ablation. Follow-up methods were variable between the four studies and included clinic visits at
3 or 6 month intervals, and either Holter or transtelephonic monitoring at variable intervals.
4